Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

The Global RDH12 Alliance will provide Opus with up to $1.6 million to codevelop a gene therapy for RDH12-associated Leber congenital amaurosis.